FDA warned Integra LifeSciences over bacterial toxin test and sterilization failures at three medical device plants.
What happened
FDA inspected three Integra medical device facilities in Massachusetts and New Jersey in 2024 and issued Form FDA 483 observations (inspection findings). It found the company released surgical patties and Duraform lots after out-of-specification endotoxin (bacterial toxin) results without complete investigations, and kept using ethylene oxide sterilization equipment after failed requalification criteria. The letter also cites corrective-action, cleanroom contamination, and process-validation problems.
What FDA found
Integra released surgical patties and Duraform lots after out-of-specification bacterial endotoxin results without fully investigating the manufacturing cause, and it retested even though its procedure did not allow retesting.
21 CFR § 820.90(a)At Plainsboro, endotoxin tests that failed the coefficient-of-variation limit were repeatedly retested until they passed, and the procedure did not say when retests were allowed or which result counted.
21 CFR § 820.80(a)The Mansfield pyrogen testing procedure did not require adequate out-of-specification investigations, retest limits, representative sampling, or recording endotoxin units in device history records before release.
21 CFR § 820.80(d)Integra did not evaluate site corrective and preventive action (CAPA) records for escalation to corporate-wide CAPAs, and it used quality plans to fix quality-system problems without the required CAPA steps.
21 CFR § 820.100(a)Integra did not adequately assess ethylene oxide sterilization requalification failures, continued using a vessel after failed criteria, and did not account for a supplier's lower pouch-seal specification in validation.
21 CFR § 820.75(c)Cleanroom particulate excursions near equipment were called low risk without adequate investigation, and a Plainsboro action limit was set at the maximum allowed level, leaving no room to act before exceeding it.
21 CFR § 820.70(e)
What FDA wants
FDA tells Integra to promptly correct the violations and warns that failure may lead to seizure, injunction, and civil money penalties. It also asks for results of the planned effectiveness check for the endotoxin testing CAPAs; no response deadline is stated in the provided letter.
Who should pay attention
- hospital and surgical staff using neurological or collagen implants
- companies buying surgical patties or collagen devices from contract manufacturers
- quality teams at device makers with shared sterilization or supplier-change issues
This is a summary. Read the original letter on fda.gov.